PET/MRI imaging for refractory dermatomyositis
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study uses a special PET/MRI scan to look at inflammation in the body of people with dermatomyositis that has not responded to treatment. The scan may help doctors understand the disease better and guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with dermatomyositis that has not improved with standard treatments.
- You can provide written consent to participate.
- You are not pregnant or possibly pregnant.
- You can undergo an MRI scan and lie flat for 30 minutes.
- You do not have any serious medical condition that would make the scan risky for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests an imaging medicine ([F-18]DPA-714) that can help researchers see inflammation in the brain and nervous system. It may help doctors better understand how “inflammation signals” differ across conditions like multiple sclerosis, fibromyalgia, and chronic fatigue syndrome.
This trial tests whether a special type of PET scan (using a tracer called 18F-FAPI) can see myelofibrosis activity better than standard scans. It may help doctors track the disease more accurately without needing extra biopsies.
This trial tests a new imaging scan (SPECT) that uses a special tracer (99mTc-TCR-FAPI) to see inflammation in the joints of people with rheumatoid arthritis. It aims to help doctors better understand and track disease activity.
This trial uses a special PET/CT scan with a tracer called 68Ga-FAPI-46 to see if it can better detect inflammation and scarring (fibrosis) in people with chronic diseases like scleroderma, pulmonary fibrosis, or rheumatoid arthritis. The goal is to improve diagnosis and monitoring.
This study tests a new type of PET/CT scan (FAPI-74) to see if it can detect areas of scarring (fibrosis) in the body. It may help doctors better understand and monitor conditions like certain cancers, infections after transplants, and heart inflammation.
This study uses a new type of PET/CT scan with a tracer called 68Ga-FAPI to help diagnose myelofibrosis, see how advanced it is, and check if treatment is working. It may help doctors better understand your condition and plan your care.
Hear when a new Refractory Dermatomyostitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.